# OnCo record paper-lehmann-tnbctype-4-refinement-plos-one-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-lehmann-tnbctype-4-refinement-plos-one-2016" ;
  schema:name "Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection"@en ;
  schema:description "The 2016 revision that cut the six triple-negative subtypes to four after showing the immune and stem-like signals came from surrounding cells, and found that response to standard chemotherapy before surgery ranged from 41 percent in basal-like 1 to 18 percent in basal-like 2."@en ;
  schema:url <https://onco.cc/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1371/journal.pone.0157368>, <https://pubmed.ncbi.nlm.nih.gov/27310713/> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1371/journal.pone.0157368> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Lehmann BD, Jovanović B, Chen X, et al." ;
  onco:related <https://onco.cc/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/rna-seq/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:institutions <https://onco.cc/institutions/vanderbilt-ingram/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/tils/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-tumor-heterogeneity/> .